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Abstract
The ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) is a measure used to diagnose
airflow obstruction and is highly heritable. We performed a genome-wide association study in 7,691 Framingham Heart
Study participants to identify single-nucleotide polymorphisms (SNPs) associated with the FEV1/FVC ratio, analyzed as a
percent of the predicted value. Identified SNPs were examined in an independent set of 835 Family Heart Study participants
enriched for airflow obstruction. Four SNPs in tight linkage disequilibrium on chromosome 4q31 were associated with the
percent predicted FEV1/FVC ratio with p-values of genome-wide significance in the Framingham sample (best p-
value = 3.6e-09). One of the four chromosome 4q31 SNPs (rs13147758; p-value 2.3e-08 in Framingham) was genotyped in
the Family Heart Study and produced evidence of association with the same phenotype, percent predicted FEV1/FVC (p-
value = 2.0e-04). The effect estimates for association in the Framingham and Family Heart studies were in the same
direction, with the minor allele (G) associated with higher FEV1/FVC ratio levels. Results from the Family Heart Study
demonstrated that the association extended to FEV1 and dichotomous airflow obstruction phenotypes, particularly among
smokers. The SNP rs13147758 was associated with the percent predicted FEV1/FVC ratio in independent samples from the
Framingham and Family Heart Studies producing a combined p-value of 8.3e-11, and this region of chromosome 4 around
145.68 megabases was associated with COPD in three additional populations reported in the accompanying manuscript.
The associated SNPs do not lie within a gene transcript but are near the hedgehog-interacting protein (HHIP) gene and
several expressed sequence tags cloned from fetal lung. Though it is unclear what gene or regulatory effect explains the
association, the region warrants further investigation.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth
leading cause of death in the US and one of the most prevalent
disabling diseases of adults. One of the defining features of COPD
is airflow obstruction that is not fully reversible when contrasting
measured spirometry before and after administration of a
bronchodilator medication. A diagnosis of airflow obstruction is
made utilizing the ratio of the spirometric measures forced
expiratory volume in the first second (FEV1) to forced vital
capacity (FVC). The FEV1/FVC ratio is reduced in obstructive
lung diseases, most notably COPD and asthma. FEV1, a measure
of airflow, is commonly used to predict clinical outcomes, grade
severity and follow the natural history of the disease in staging
systems such as the one employed by The Global Initiative for
Chronic Obstructive Lung Disease [1]. Low FEV1 can be due to
restrictive or obstructive lung disease, whereas low FEV1/FVC is a
more specific indicator of airflow obstruction.
Tobacco smoking is the major environmental cause of COPD,
but genetic factors also influence the risk of developing this
condition. COPD aggregates in families [2], and spirometric
measurements of pulmonary function are heritable [3,4]. A severe
deficiency of alpha-1-antitrypsin, caused by mutations of the
SERPINA1 (AAT) gene, causes premature and severe emphysema
(OMIM 107400); however, SERPINA1 mutations explain only a
small proportion of cases of COPD. The association of SERPINE2
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SNPs with risk of COPD has been successfully replicated in
independent samples [5], but the functional role of SERPINE2 in
the development of COPD remains to be characterized [6]. A
number of other candidate gene associations reported in the
literature have failed to replicate convincingly [7]. At present, the
genetic factors other than SERPINA1 mutations that increase
susceptibility to COPD remain uncertain.
One approach to identifying genes as potential risk factors for
COPD is by studying quantitative measures of lung function in
population based samples using genome-wide linkage and
association methods. Genome-wide linkage to quantitative spi-
rometry traits such as FEV1, FVC, and the FEV1/FVC ratio [8]
has led to the identification of positional candidate genes like
SMOC2 [9,10]. Quantitative spirometry traits were examined in a
previous genome-wide association study using 70,987 single
nucleotide polymorphisms (SNPs) in about 1220 related individ-
uals in the Framingham Heart Study [11]. Though no results met
the strict criteria for genome-wide significance, GSTO2 emerged as
a candidate gene that warranted replication studies.
The Framingham Heart Study (FHS) has collected spirometry
and smoking history data on three generations of adults, and these
research participants provided DNA samples that have recently
been genotyped for 550,000 SNPs using microarray technology.
These genotype and phenotype data, which have been made
publicly available through the NHLBI’s SNP Health Associa-
tion Resource (SHARe) initiative (http://public.nhlbi.nih.gov/
GeneticsGenomics/home/share.aspx), provide a powerful re-
source to conduct genome-wide association studies with the goal
of discovering novel genetic risk factors for airflow obstruction.
Since the prevalence of moderate to severe COPD in this
population based sample is low and genetic studies of quantitative
traits are thought to have higher statistical power than dichoto-
mous traits, we report here the findings from a genome-wide
association (GWA) study for the quantitative pulmonary function
measure FEV1/FVC, analyzed as a percent of predicted.
The Family Heart Study was developed from existing
epidemiologic studies in Forsyth County, NC, Framingham,
MA, Minneapolis, MN, and Salt Lake City, UT. Participants
were invited to provide a family health history and of those
responding, a subset of families was enrolled for a clinical
examination that included cross-sectional spirometry and smoking
history data as well as DNA for genetic studies [12]. Genome-wide
linkage analyses were previously reported for FEV1, FVC, and
FEV1/FVC [13], and many of the DNA samples were available
for further study. We now report the results of SNP association
with the percent predicted FEV1/FVC ratio in the Family Heart
Study sample that was undertaken to evaluate independent
replication of findings arising in the Framingham GWA.
Methods
Ethics Statement
All participants provided written informed consent and local
institutional review boards approved the study protocols.
Framingham and Family Heart Samples
The Framingham Heart Study has measured spirometry on
three generations of families from clinical examinations that began
in 1948. Original Cohort participants, their Offspring and
offspring spouses, and the Third Generation (GEN3) of partici-
pants were recruited and examined in Framingham, Massachu-
setts [14]. A total of 7691 white participants had both genotyping
and spirometry available.
A sample of 835 non-asthmatic white Family Heart Study
participants, including 225 cases of spirometrically defined airflow
obstruction and 610 controls, was used to screen Framingham
GWA analysis results. The sample excluded Framingham field
center participants in order to define an independent replication
sample that included 91 families (545 individuals) with 81 cases of
spirometrically defined obstructive pulmonary disease and a case/
control sample with an additional 144 cases and 146 controls
frequency-matched to cases on age and smoking status. Case and
control criteria for airflow obstruction were defined by spirometry
as described below. Controls included both family members of
cases and unrelated controls.
Percent Predicted Spirometry Phenotypes
Spirometry from each Framingham participant’s latest exam-
ination with acceptable pulmonary function data was used;
eligible examinations included Cohort exams 19, 17, 16 and 13,
Offspring exams 7, 6, 5, and 3, and GEN3 exam 1. Predicted
values for FEV1 and FEV1/FVC were calculated using cohort
and gender-specific regression models predicting spirometry
measurements on the basis of age, age squared, and height
squared among Framingham subjects who were lifetime non-
smokers and had no history of chronic bronchitis, pulmonary
disease, COPD/emphysema, asthma, or wheezing. The percent
predicted value was calculated by dividing the observed by the
predicted value. Standardized residuals were then created by
regressing the percent predicted on smoking status (never,
former, current) coded using dummy variables to indicate
current smoking (yes/no) and former smoking (yes/no), pack-
years, and body mass index (BMI: kg/m2), in cohort and gender-
specific models. The standardized residuals for percent predicted
FEV1 and FEV1/FVC ratio were correlated at 0.52 (p-
value,0.0001) in the Framingham participants. The percent
predicted FEV1/FVC ratio standardized residual was examined
as the primary quantitative trait in the GWA.
Spirometry in the Family Heart Study was performed at only
one point in time, thus the data are cross-sectional. The observed
spirometry was compared to expected values in order to define a
percent predicted measure that was further adjusted for smoking
status, pack-years, and BMI in gender-specific models using all
Author Summary
Cigarette smoking is the primary risk factor for impaired
lung function, yet only 20% of smokers develop chronic
obstructive pulmonary disease (COPD). This observation,
along with family studies of lung function and COPD,
suggests that genetic factors influence susceptibility to
cigarette smoke. We examined the relationship between
common genetic variants and measures of lung function in
a sample of 7,691 participants from the Framingham Heart
Study and confirmed our observations in 835 participants
from the Family Heart Study selected to include cases of
airflow obstruction. We identified a variant on chromo-
some 4 that was strongly associated with FEV1/FVC in the
Framingham Study and confirmed the association in the
Family Heart Study. The accompanying manuscript iden-
tified the same region to be associated with COPD. Several
interesting genes are present in the region that we
identified, including a gene (HHIP) interacting with a
biological pathway involved in lung development, but it is
not yet clear which gene in the region explains the
association. Our results identified a region of chromosome
4 that warrants further study to understand the genetic
effects influencing lung function.
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participants with spirometry. The subset of participants genotyped
was analyzed with a FEV1/FVC ratio standardized residual
generated from the larger sample, paralleling the analysis of
Framingham data.
Dichotomous Airflow Obstruction Phenotypes
In both Framingham and Family Heart studies, a dichotomous
trait for airflow obstruction was defined by a percent predicted
FEV1/FVC ratio less than 90 and a percent predicted FEV1
less than 80. These values were selected to standardize a
definition for mild airflow obstruction across cohorts and
gender using the percent predicted FEV1/FVC ratio, which
accounts for the normal reduction in FEV1/FVC with
increasing age [15]. Controls used in these analyses were
required to have neither a percent predicted FEV1/FVC ratio
less than 90 nor a percent predicted FEV1 less than 80, which
results in a smaller sample size for studies of the dichotomous
trait compared to studies of percent predicted FEV1/FVC
ratio. In Framingham, asthma was classified based on self-
report at Cohort exam 1, 3, or 5, Offspring exam 7, and
GEN3 exam 1. In the Family Heart Study, asthma was also
classified based on self-report.
Affymetrix 550K Genotyping
Framingham participants were genotyped using the Affymetrix
(Santa Clara, CA) GeneChip Human Mapping 500K Array Set,
which was comprised of two arrays generating approximately
262,000 SNPs with Nsp arrays and 238,000 SNPs with Sty arrays.
An additional Affymetrix 50K Array (HuGeneFocused50K) with
gene-centric and coding SNPs was also genotyped for a total of
approximately 550K SNPs.
Analysis of Genotyped SNPs
For population-based analyses of quantitative traits, we
examined standardized residuals using linear-mixed effects
(LME) models with fixed effects for SNP genotypes and random
effects for individuals correlated within families due to polygenic/
familial shared effects [16]. Logistic regression via generalized
estimating equations (GEE) to account for correlated observations
in pedigrees and adjust for covariates was used for dichotomous
outcomes. Family-based association tests were implemented in the
FBAT software [17]. To assess population stratification in the
Framingham sample, principal components were generated using
Eigenstrat [18]. None of the first ten components was significantly
(p,0.05) related to the percent predicted FEV1/FVC ratio,
suggesting that population substructure was unlikely to confound
the population-based association analysis. Analyses implemented
additive genetic models using individuals with $97% genotyping
call-rate. SNP results were filtered on Hardy-Weinberg Equilib-
rium p-value of 161026, SNP call-rate of 95%, and Minor Allele
Frequency of 0.01.
Genotype Imputation and Analysis
Imputation implemented in MACH [19] (http://www.sph.
umich.edu/csg/abecasis/MACH/) was applied to the GWA data
to produce imputed genotypes on 2,540,223 HapMap SNPs. An
additive model was used for association analysis of the dosage data
for imputed genotypes, which provided information on new SNPs
and new genotypes for SNPs with previously missing data. The
ratio of the empirically observed dosage variance to the expected
(binomial) dosage variance was computed as a quality control
metric for imputed SNPs [20], and only those with a ratio above
0.9 were considered of high quality.
Replication in Family Heart Study Participants
LME model results were used to rank the regions identified in
the GWA of percent predicted FEV1/FVC in Framingham data.
A SNP from each of the ten regions with the lowest LME p-values
was genotyped in the set of 835 Family Heart Study participants.
As only one region met genome-wide statistical significance,
selecting ten regions for follow-up was arbitrary. Genotyping was
performed using TaqMan technology implemented on the ABI
PRISM 7900HT Sequence Detection system at Boston University
School of Medicine. The ten SNPs were analyzed for association
with the percent predicted FEV1/FVC phenotype in the Family
Heart Study sample. Based on testing association to ten SNPs
representing the top regions of association, a Bonferroni p-value of
0.005 was considered evidence of association in the replication
study. Results from screening these top ten regions led to testing
additional SNPs and phenotypes on chromosome 4.
Results
Descriptive statistics of the Framingham and Family Heart
Study samples are provided in Table 1. Though the proportion of
Table 1. Descriptive characteristics of the Framingham and Family Heart Study participants.
Framingham Cohort Framingham Offspring Framingham GEN3 Family Heart Study
Male
(n =326)
Female
(n =556)
Male
(n =1508)
Female
(n =1696)
Male
(n=1708)
Female
(n=1897)
Male
(n =417)
Female
(n=418)
Age 71.665.3 72.065.5 59.869.6 59.669.7 40.368.7 40.168.7 55.2612.8 54.2612.9
BMI 27.063.9 26.464.8 28.564.4 27.565.8 27.964.5 26.066.0 27.964.3 27.065.9
Current smoking 12.6% 15.1% 15.1% 16.3% 15.9% 14.8% 23.7% 23.2%
Former smoking 59.8% 36.5% 53.3% 44.8% 24.6% 30.6% 46.3% 25.4%
Pack-years* 36.8622.7 22.8620.3 32.1624.7 23.8621.4 16.2616.0 11.8612.1 37.6628.7 29.0622.0
% predicted FEV1 92.7620.2 99.8620.1 93.2617.4 94.4617.7 97.8612.2 98.5612.0 91.0621.1 95.1620.5
% predicted FEV1/FVC 92.7611.9 95.1610.6 95.9610.6 96.0610.4 98.567.9 98.767.5 89.9613.2 90.5611.0
% airflow obstruction 19.9% 10.3% 12.3% 11.3% 3.8% 3.1% 30.2% 23.2%
% asthma 4.7% 2.9% 10.1% 13.3% 13.3% 16.8% 0% 0%
*Pack-year mean and standard deviation computed among former and current smokers only.
doi:10.1371/journal.pgen.1000429.t001
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current smokers is similar across Framingham cohorts, GEN3 had
more never-smoking participants than did the older generations.
The proportion of participants reporting asthma was greater in the
younger generations, and the proportion of participants meeting
criteria for COPD was higher in the older generations. The higher
proportion of current smokers and airflow obstruction in the
Family Heart Study reflects the selection of the sample.
The GWA results for percent predicted FEV1/FVC based on
LME analysis are reported in Table 2 and a Q-Q plot of the
results is presented in Figure 1. Ten top regions of interest are
described based on 18 SNPs with p-values less than 1.5E-05. The
genomic inflation factor value of 1.043 suggested the results were
appropriately distributed. Only one region (four SNPs) reached the
threshold for genome-wide statistical significance (p,5E-08),
which was located on chromosome 4 in an intergenic region near
the gene HHIP. Also of note among the top regions identified was
theMMP15 gene, which belongs to the matrix metalloproteinase
(MMP) family. MMPs have been previously implicated in
pulmonary disease, although this particular gene has not been
related to COPD development. Table 2 also presents corre-
sponding p-values from analysis of adjusted standardized
residuals with FBAT, which is a more conservative test than
LME but protects against population stratification. The FBAT
results in the HHIP region include the lowest FBAT p-values
observed genome-wide and support the strong association
observed using the LME model.
The results of the GWA for percent predicted FEV1/FVC using
imputed SNP genotypes were evaluated to determine whether new
regions were implicated by the improved SNP density and
whether the associations improved by imputing missing values
for genotyped SNPs. The region with the best p-values continued
to be the chromosome 4 region near HHIP, and the results from
imputed genotypes in this region are depicted in Figure 2. The p-
value for rs13147758 was slightly better in the results from
imputed genotypes, and a total of 27 SNPs in the region (including
the four reported in Table 2) met the criterion for genome-wide
statistical significance (p,5E-08). The colors plotted in Figure 2
reflect the linkage disequilibrium (LD) of each SNP with
rs13147758 and demonstrate the strong LD among the SNPs
with the smallest p-values. All SNP results for association with
percent predicted FEV1/FVC with a p-value,0.001 for LME
analysis of high quality imputed genotypes have been included in
Table S1 in the Online Data Supplement.
Table 3 reports the association results for the top GWA regions
screened in 835 Family Heart Study participants. The SNP with
the best overall p-value (rs11100860 on chromosome 4) was
ordered for genotyping, but the assay did not meet Applied
Biosystems’ internal quality control criteria and therefore was not
genotyped. SNP rs13147758, with the second best overall p-value,
was therefore studied to represent the chromosome 4 region. The
SNP on chromosome 5, rs7707619, had a minor allele frequency
of 1% in Framingham, and was not observed in the Family Heart
Study samples. Of the nine SNPs studied for association with the
percent predicted FEV1/FVC ratio in the Family Heart Study,
only one p-value was observed that met a Bonferroni corrected
cutoff for statistical significance (p,0.005), which was located in
the chromosome 4 GWA significant region (rs13147758; p-
value = 2.0E-04).
To further evaluate the region of chromosome 4 that
demonstrated replication with SNP rs13147758, we examined
association with additional SNPs and additional phenotypes in the
Family Heart Study. Table 4 presents association to FEV1, the
FEV1/FVC ratio, and a dichotomous airflow obstruction trait in
the ever-smoking participants. When the analysis was restricted to
subjects with a history of ever smoking cigarettes, the association
between rs13147758 genotype and the FEV1/FVC ratio had a
Table 2. Top 10 regions implicated by LME results for percent predicted FEV1/FVC in an additive genetic model studying
genotyped SNPs in the Framingham Heart Study.
rs# Chrom position MAF FBAT p-value*
LME beta
estimate LME p-value Genes within 100 kb
rs11100860 4 145698589 0.388 1.31E-06 0.104 3.55E-09 HHIP
rs13147758 4 145679680 0.385 6.92E-06 0.098 2.31E-08
rs7655625 4 145705365 0.389 6.27E-06 0.098 2.4E-08 HHIP
rs1980057 4 145705188 0.387 6.54E-06 0.097 2.7E-08 HHIP
rs1828591 4 145700230 0.392 8.63E-06 0.090 3.83E-07 HHIP
rs1512285 4 145670409 0.461 0.00013 20.09 2.93E-06
rs973796 4 145643418 0.369 0.000157 0.08 7.14E-06
rs6471895 8 61787503 0.037 0.0161 20.221 5.8E-07 CHD7
rs1017444 2 117491841 0.036 0.00015 20.212 3.12E-06
rs17086172 18 68378001 0.057 0.119 20.170 3.31E-06 CBLN2
rs7707619 5 72715410 0.011 0.00833 20.356 4.22E-06 FOXD1
rs994960 3 73814606 0.482 9.82E-05 20.076 6.79E-06 PDZRN3
rs2137064 3 73833683 0.473 4.06E-05 20.075 9.88E-06 PDZRN3
rs1877252 3 73810230 0.482 0.000185 20.074 1.01E-05 PDZRN3
rs17646919 22 28730861 0.085 0.0362 0.134 9.84E-06 MTMR3
rs2304488 16 56631711 0.202 0.000672 20.092 1.09E-05 MMP15
rs573461 7 51403173 0.279 0.095 0.083 1.26E-05 COBL
rs2456526 15 50876734 0.138 0.0197 20.107 1.41E-05 ONECUT1
*The direction of effect indicated by the sign of the FBAT Z score was consistent with the direction of the LME beta estimate for all SNPs.
doi:10.1371/journal.pgen.1000429.t002
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smaller p-value (2.2E-06) and larger estimate of effect. The SNP
identified with association to the FEV1/FVC ratio phenotype
was also statistically significant for FEV1 (p = 0.0001) and
airflow obstruction (p = 6.18E-06) in smokers. Furthermore,
minor alleles at neighboring SNPs exhibited association to lower
lung function and increased risk of airflow obstruction (e.g.
rs17019336: OR= 1.76, p = 0.004; rs2353397: OR= 1.65,
p = 0.003).
Figure 1. Quantile-Quantile Plot of GWA results for percent predicted FEV1/FVC.
doi:10.1371/journal.pgen.1000429.g001
Figure 2. Plot of chromosome 4 association with percent
predicted FEV1/FVC in imputed Framingham Heart Study data.
X-axis is the physical position in kb with arrows denoting genes and
expressed sequence tags in the region, the left y-axis plots the 2log(p-
value), and the right y-axis plots the CEPH recombination rate. The blue
diamond identifies the labeled SNP of interest, and LD with the SNP is
depicted by color of additional diamonds: red-strong LD (r2$0.8),
orange-moderate LD (0.5#r2,0.8), yellow-low LD (0.2#r2,0.5), white-
no LD (r2,0.2).
doi:10.1371/journal.pgen.1000429.g002
Table 3. Association results for SNPs in the top 10 GWA
regions identified in Framingham and examined in 835 Family
Heart Study participants for association to percent predicted
FEV1/FVC.
rs# Chrom position MAF
Beta
estimate p-value
Gene
region
rs13147758 4 145679680 0.411 0.25 2.0E-04 HHIP
rs6471895 8 61787503 0.025 20.17 0.33 CHD7
rs1017444 2 117491841 0.038 20.38 0.03
rs17086172 18 68378001 0.071 20.04 0.77 CBLN2
rs7707619 5 72715410 0 * * FOXD1
rs994960 3 73814606 0.472 20.12 0.06 PDZRN3
rs17646919 22 28730861 0.07 20.15 0.27 MTMR3
rs2304488 16 56631711 0.223 0.04 0.68 MMP15
rs573461 7 51403173 0.277 0.06 0.44 COBL
rs2456526 15 50876734 0.13 0.07 0.48 ONECUT1
*SNP was genotyped and found to be non-polymorphic in the sample.
doi:10.1371/journal.pgen.1000429.t003
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Table 5 presents the results of the Family Heart Study sample
alongside Framingham results for rs13147758 and includes
analyses of FEV1, a dichotomous airflow obstruction trait, and
analyses restricted to smokers. The results demonstrate a modest
association with FEV1 in the Framingham sample, and a
significant association with FEV1 in the Family Heart Study.
When restricted to ever smokers, the effect size and p-values for
FEV1 and the ratio improve in the Family Heart sample, but not
in Framingham. For analysis of the dichotomous airflow
obstruction phenotype, restricting the analysis to ever smokers
improves the effect size and p-value in both samples. The minor
allele of rs13147758 was protective for airflow obstruction among
ever smokers in both samples, though only a trend toward
statistical significance was seen in the Framingham sample.
Discussion
The GWA results for percent predicted FEV1/FVC in the
Framingham Heart Study identified a region on chromosome
4q31 around 145.68 Mb with LME p-values that achieved
genome-wide statistical significance (rs13147758 p= 2.31E-08 for
genotyped SNP; p= 1.95E-08 for the same SNP imputed). FBAT
analyses, which protect against false positive results arising from
population stratification, also provided strong support for an
association (p = 6.9E-06). Screening the top ten identified regions
in 835 Family Heart Study participants further implicated the
chromosome 4 region, and did not support the SNP association in
the other nine regions. Though the replication sample size may
have had limited power to detect SNPs with smaller MAFs or
effect sizes, the identification of replication on chromosome 4 is not
likely to be a false positive. The minor allele of rs13147758 with a
frequency of 39% was associated with higher levels of the FEV1/
FVC ratio and a 15–55% reduced risk of airflow obstruction among
smokers. The reported beta estimates were on the scale of the
standardized residual and reflect an approximately 1% increase in
the percent of predicted FEV1/FVC ratio. For example, among
Framingham smokers, the unadjusted mean percent predicted
FEV1/FVC ratio was 94.4%, 95.5%, and 96.3% for the
homozygous major allele, heterozygous, and homozygous minor
allele genotypes, respectively.
In a related publication describing results for a GWA of COPD,
the chromosome 4q31 region was identified among the top 100
SNP results and replicated in two independent populations [21].
The two SNPs reported with combined p-values of 1.5E-07 and
1.7E-07 both exhibit strong LD with rs13147758 (r2 = 0.97 in
HapMap CEPH). The independent finding for this region based
on samples ascertained for moderate to severe COPD provides
compelling evidence for the association on chromosome 4q31.
The genomic region on chromosome 4 does not lend itself to
easy interpretation of the SNP association results. The closest
characterized gene, hedgehog-interacting protein (HHIP), which is
located distal to the associated SNPs, is an intriguing candidate
because the hedgehog signaling pathway is known to influence
lung development [22] and is activated in the airways during
repair of injury [23]. However, the association does not explicitly
implicate the gene. The specific SNP (rs13147758) that was
replicated lies 107 kb 59 of the start site of HHIP and does not
exhibit LD with SNPs located within the HHIP gene transcript.
Table 4. SNP association results for the Family Heart Study smokers (N= 485) in the chromosome 4 region.
SNP Position MAF FEV1 beta FEV1 p-value Ratio beta Ratio p-value
Airflow
Obstruction OR(a)
Airflow Obstruction
p-value(a)
rs17019336(b) 145553059 0.23 20.222 0.052 20.294 0.01 1.76 0.004
rs13147758 145679680 0.41 0.341 0.0001 0.397 2.24E-06 0.45 6.18E-06
rs2353397 145737028 0.44 20.154 0.09 20.138 0.14 1.65 0.003
rs2035901 145741317 0.49 0.082 0.37 0.107 0.26 0.67 0.02
rs6537302 145807566 0.46 0.082 0.38 0.057 0.59 0.69 0.04
(a)N = 185 cases, 226 controls.
(b)SNP had the lowest p-value for FEV1 (p = 1.7E-04) in Framingham results for this region.
doi:10.1371/journal.pgen.1000429.t004
Table 5. Association results for rs13147758 with percent predicted FEV1/FVC, FEV1, and airflow obstruction across studies and in
subset of ever smokers.
Phenotype Framingham Heart Study Family Heart Study
N=7691 N=4141 smokers N=823 N=485 smokers
Beta est p-value
Beta est
smokers
p-value
smokers Beta est p-value
Beta est
smokers p-value smokers
FEV1/FVC 0.098 2.31E-08 0.09 8.1E-05 0.246 0.0002 0.397 2.2E-06
FEV1 0.038 0.03 0.04 0.09 0.196 0.004 0.341 0.0001
623 cases, 5902 controls Smokers: 506 cases, 2884 controls 223 cases, 455 controls Smokers: 185 cases, 226 controls
OR all p-value OR smokers p-value OR all p-value OR smokers p-value
Airflow
obstruction
0.9 0.14 0.85 0.06 0.61 0.005 0.45 6.18E-06
doi:10.1371/journal.pgen.1000429.t005
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Another gene, CR620567, is transcribed on the opposite strand,
and rs13147758 is 104 kb 39 from the end of that gene. The
colored arrows in Figure 2 show the genes9 orientation. Also
shown is the presence of an expressed sequence tag (EST) in the
same region. Three overlapping ESTs transcribed on the opposite
strand, including W05107, BX104541 and AI822050 (labeled in
Figure 2 only as BX104541), extend between 225–300 kb in
length and were cloned from a Soares fetal lung library
(NbHL19W) [24,25]. The location of the association leaves open
the possibility for regulatory effects on HHIP, the uncharacterized
ESTs from fetal lung, or members of the GYP gene cluster.
Though located nearly 400 kilobase pairs from the associated
SNPs, the gene glycophorin A (GYPA) is the nearest known proximal
gene and lies adjacent to its homolog GYPB. Glycophorins are
proteins of the red blood cell membrane, and glycophorin expression
has been shown to be lower among COPD patients than controls
[26]. The red blood cell is susceptible to oxidative alterations, which
have been proposed as a useful marker for cell damage in COPD
[27]. Review of the imputed data results for a missense SNP in GYPA
showed a modest association (rs7658293; p=0.037), with a common
minor allele associated with a decreased FEV1/FVC ratio, and
additional SNPs in LD exhibited similar p-values. However, the
GYPA missense SNP does not exhibit LD with the replicated SNP
rs13147758 (HapMap CEPH r2=0.006). In contrast to SNP results
within GYPA, none of the SNPs within HHIP had p-values less than
0.05 for association with percent predicted FEV1/FVC.
The GWA results provide only limited insight into the
functional role of the most strongly associated region. It is not
clear if the chromosome 4 region is associated with pulmonary
disease or variability in pulmonary function in normal populations.
The definitions of airflow obstruction and asthma in these
observational studies have limitations. Both studies use spirometry
to define airflow obstruction, but post-bronchodilator spirometry is
not available, which may misclassify some individuals with
reversible airflow obstruction as seen in asthma. However, results
excluding diagnosed asthmatic participants (data not shown)
suggest that the association is not driven by an asthma phenotype.
GWA analyses for the FEV1/FVC ratio after exclusion of self-
reported asthma identified the same chromosome 4 region with
the best p-value at genome-wide significance, and all the results in
the Family Heart Study represent a non-asthmatic sample.
Though we have not identified a functional variant in the region,
the replication of genome-wide significant results suggests that this
intergenic region of chromosome 4 may influence pulmonary
function and risk of obstructive pulmonary disease.
The related manuscript describing a GWA for COPD identified
association to a region of chromosome 15 that includes the
nicotinic acetylcholine receptor (CHRNA3/5) [21]. Two SNPs
were identified to be associated with COPD in the discovery
cohort and replicated in two independent populations. We
evaluated whether these SNPs (rs8034191 and rs1051730)
provided evidence of association using the Framingham imputed
genotypes, as they were not directly genotyped, but neither SNP
was significantly associated with percent predicted FEV1/FVC or
dichotomous airflow obstruction. Reviewing results across the
region, we noted that SNPs in the nearby IREB2 gene provided
evidence for association to percent predicted FEV1/FVC (best p-
value = 0.006). This lack of a specific replication to CHRNA3/5
may reflect differences in the severity of airflow obstruction present
in the population based Framingham study in contrast to a
clinically ascertained COPD case sample. Further, as this locus has
been reported to be associated with nicotine dependence [28,29],
differences in smoking behavior may influence the power to detect
an association. As the Framingham study represents three
generations ascertained at different time points, secular trends in
smoking behavior may confound the association despite adjust-
ment for pack-years within cohort.
We have provided, in the online supplement, a resource of all
SNP association results with nominal statistical significance
(p,0.001) for the percent predicted FEV1/FVC to facilitate
future efforts to replicate SNP association with pulmonary
phenotypes. The region of association on chromosome 4 warrants
follow-up to explore the expressed sequence in fetal and adult
lung, and to evaluate the relationship of the associated SNPs to
gene expression of the nearby genes HHIP and GYPA and the
ESTs. Our results demonstrate the utility of genome-wide
association analysis in the identification of genetic determinants
of obstructive lung diseases.
Supporting Information
Table S1 All SNPs generating a p-value,0.001 for LME
analysis of high quality (ratio.0.9) imputed genotypes for percent
predicted FEV1/FVC in an additive genetic model.
Found at: doi:10.1371/journal.pgen.1000429.s001 (4.81 MB
DOC)
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